An "immunogenic composition" is not a vaccine (T 0070/23)

In the recent Board of Appeal decision T 0070/23, GSK argued that its "immunogenic composition" product claim should be interpreted as limited by its efficacy as a vaccine, particularly in view of a description definition of the term. However, the Board of Appeal found both that product claims should not be interpreted as comprising therapeutic effects and that the description definitions do